Literature DB >> 14668813

Aromatase inhibitors for breast cancer: lessons from the laboratory.

Stephen R D Johnston1, Mitch Dowsett.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14668813     DOI: 10.1038/nrc1211

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


× No keyword cloud information.
  85 in total

Review 1.  Identifying and targeting tumor-initiating cells in the treatment of breast cancer.

Authors:  Wei Wei; Michael T Lewis
Journal:  Endocr Relat Cancer       Date:  2015-04-15       Impact factor: 5.678

2.  Exemestane in the prevention setting.

Authors:  Jennifer Keating Litton; Therese B Bevers; Banu K Arun
Journal:  Ther Adv Med Oncol       Date:  2012-05       Impact factor: 8.168

3.  Population pharmacokinetic analysis of letrozole in Japanese postmenopausal women.

Authors:  Hiromi Tanii; Yoshihisa Shitara; Toshiharu Horie
Journal:  Eur J Clin Pharmacol       Date:  2011-04-15       Impact factor: 2.953

Review 4.  Natural products as aromatase inhibitors.

Authors:  Marcy J Balunas; Bin Su; Robert W Brueggemeier; A Douglas Kinghorn
Journal:  Anticancer Agents Med Chem       Date:  2008-08       Impact factor: 2.505

5.  A transformation in the mechanism by which the urokinase receptor signals provides a selection advantage for estrogen receptor-expressing breast cancer cells in the absence of estrogen.

Authors:  Boryana M Eastman; Minji Jo; Drue L Webb; Shinako Takimoto; Steven L Gonias
Journal:  Cell Signal       Date:  2012-05-19       Impact factor: 4.315

6.  Anti-proliferative and pro-apoptotic effects of rosemary and constituent terpenoids in a model for the HER-2-enriched molecular subtype of clinical breast cancer.

Authors:  Nitin Telang
Journal:  Oncol Lett       Date:  2018-07-31       Impact factor: 2.967

Review 7.  Biological determinants of endocrine resistance in breast cancer.

Authors:  Elizabeth A Musgrove; Robert L Sutherland
Journal:  Nat Rev Cancer       Date:  2009-09       Impact factor: 60.716

8.  Wnt-5a signaling restores tamoxifen sensitivity in estrogen receptor-negative breast cancer cells.

Authors:  Caroline E Ford; Elin J Ekström; Tommy Andersson
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-23       Impact factor: 11.205

9.  Survival signals generated by estrogen and phospholipase D in MCF-7 breast cancer cells are dependent on Myc.

Authors:  Vanessa Rodrik; Yang Zheng; Faith Harrow; Yuhong Chen; David A Foster
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

10.  A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer.

Authors:  Maïa Chanrion; Vincent Negre; Hélène Fontaine; Nicolas Salvetat; Frédéric Bibeau; Gaëtan Mac Grogan; Louis Mauriac; Dionyssios Katsaros; Franck Molina; Charles Theillet; Jean-Marie Darbon
Journal:  Clin Cancer Res       Date:  2008-03-15       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.